NCT07175688Completed
Metabolic Associated Fatty Liver Disease and Pancreatic Steatosis in Obese Versus Lean Chronic Hepatitis B Patients
Study of Metabolic Associated Fatty Liver Disease (MAFLD) and Pancreatic Steatosis in Obese Versus Lean Chronic Hepatitis B Patients
Source: ClinicalTrials.gov · Last updated 16 Sept 2025
Brief summary (registry, in English)
This study aimed to evaluate the prevalence of metabolic associated fatty liver disease (MAFLD), fatty pancreas and hepatic fibrosis in obese and lean patients with chronic hepatitis B; either treatment naive or on treatment with first-line nucleos(t)ide analogs.
- Status (registry)
- Completed
- Study type
- Observational
- Enrollment
- 217 (actual)
- First submitted
- 9 Sept 2025
- Start date
- 10 Apr 2022
- Primary completion date
- 1 Jan 2024
- Lead sponsor
- Tanta University
- NCT number
- NCT07175688
What you commit to
- Study type: Observational
- Participants enrolled: 217
- From 10 Apr 2022 to the primary completion date, 1 Jan 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Hepatitis C virus (HCV) antibody positive.
- Human immunodeficiency viruses (HIV).
Other
- Hepatocellular carcinoma (HCC).
- Pregnancy.
Who the study is looking for
- Age 18 years or older.
- Both sexes.
- Chronic hepatitis B patients.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tanta university Coordinator of this site? Confirm its status | Tanta | Egypt | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.